Latest Tamir Biotechnology (ACEL) Headlines N
Post# of 9
Posted On: 03/08/2014 4:39:29 PM
Latest Tamir Biotechnology (ACEL) Headlines
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Global Melanoma Report - Pipeline Review
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tjxbsj/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2013" report to their offering. 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Melanoma. Scope - A snapshot of the global therapeutic scenario for Melanoma. - A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Melanoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. 30 of the Companies Involved in Melanoma Therapeutics Development - Johnson & Johnson - Vical Incorporated - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Viralytics Ltd. - GlaxoSmithKline plc - Nektar Therapeutics - Antigenics, Inc. - Inovio Biomedical Corporation - medac GmbH - Merck & Co., Inc. - Lentigen Corporation - Generex Biotechnology Corporation - Plexxikon Inc. - Amorfix Life Sciences Ltd. - Prolexys Pharmaceuticals, Inc. - Aposense Ltd. - Histogen, Inc. - Novartis AG - Aphios Corporation - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - SuperGen, Inc. - Teva Pharmaceutical Industries Limited - Alfacell Corporation - Bayer AG - MannKind Corporation For more information visit http://www.researchandmarkets.com/research/tjxbsj/melanoma
Brain Cancer - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Brain Cancer
M2 - Tue Aug 13, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qq9tr/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Advaxis, Inc. - Alfacell Corporation - AngioChem Inc. - Antigenics, Inc. - Archer Biosciences, Inc - Basilea Pharmaceutica Ltd. - Bionomics Limited - CK Life Sciences Int'l., (Holdings) Inc. - Cell Therapeutics, Inc. - Critical Outcome Technologies Inc. - DEKK-TEC, Inc. - Diffusion Pharmaceuticals LLC - Dong-A Pharmaceutical Co., Ltd. - e-Therapeutics plc - EpiCept Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hawthorn Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Nanobiotix - Neuralstem, Inc. - Philogen S.p.A. - Prana Biotechnology Limited - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - to-BBB technologies BV - TVAX Biomedical, LLC For more information visit http://www.researchandmarkets.com/research/3q...ain_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:06AM CDT
Research and Markets has announced the addition of the Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013 report to their offering. 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections. Scope - A snapshot of the global therapeutic scenario for Cytomegalovirus (HHV-5) Infections. - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2012
M2 - Tue Feb 26, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pkw3p/severe_acute) has announced the addition of Global Markets Direct's new report "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2012" to their offering. 'Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection. Scope - A snapshot of the global therapeutic scenario for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection. - A review of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection products under development by compani
Intestinal Cancer - Pipeline Review, H2 2012 Includes a Snapshot of the Global Therapeutic Scenario for Intestinal Cancer
M2 - Thu Jan 17, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/qkchs6/intestinal_cancer) has announced the addition of Global Markets Direct's new report "Intestinal Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Normal 0 false false false MicrosoftI
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Global Melanoma Report - Pipeline Review
M2 - Tue Sep 03, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tjxbsj/melanoma) has announced the addition of the "Melanoma - Pipeline Review, H2 2013" report to their offering. 'Melanoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Melanoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Melanoma. Scope - A snapshot of the global therapeutic scenario for Melanoma. - A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Melanoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. 30 of the Companies Involved in Melanoma Therapeutics Development - Johnson & Johnson - Vical Incorporated - Amgen Inc. - AstraZeneca PLC - Eli Lilly and Company - Viralytics Ltd. - GlaxoSmithKline plc - Nektar Therapeutics - Antigenics, Inc. - Inovio Biomedical Corporation - medac GmbH - Merck & Co., Inc. - Lentigen Corporation - Generex Biotechnology Corporation - Plexxikon Inc. - Amorfix Life Sciences Ltd. - Prolexys Pharmaceuticals, Inc. - Aposense Ltd. - Histogen, Inc. - Novartis AG - Aphios Corporation - Daewoong Pharmaceutical Co., Ltd. - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - SuperGen, Inc. - Teva Pharmaceutical Industries Limited - Alfacell Corporation - Bayer AG - MannKind Corporation For more information visit http://www.researchandmarkets.com/research/tjxbsj/melanoma
Brain Cancer - Pipeline Review, H2 2013 Report Gives a Snapshot of the Global Therapeutic Scenario for Brain Cancer
M2 - Tue Aug 13, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3qq9tr/brain_cancer) has announced the addition of the "Brain Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Brain Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Brain Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Advaxis, Inc. - Alfacell Corporation - AngioChem Inc. - Antigenics, Inc. - Archer Biosciences, Inc - Basilea Pharmaceutica Ltd. - Bionomics Limited - CK Life Sciences Int'l., (Holdings) Inc. - Cell Therapeutics, Inc. - Critical Outcome Technologies Inc. - DEKK-TEC, Inc. - Diffusion Pharmaceuticals LLC - Dong-A Pharmaceutical Co., Ltd. - e-Therapeutics plc - EpiCept Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hawthorn Pharmaceuticals, Inc. - Kinex Pharmaceuticals, LLC - Nanobiotix - Neuralstem, Inc. - Philogen S.p.A. - Prana Biotechnology Limited - Spectrum Pharmaceuticals, Inc. - Stemline Therapeutics, Inc. - TAU Therapeutics, LLC - to-BBB technologies BV - TVAX Biomedical, LLC For more information visit http://www.researchandmarkets.com/research/3q...ain_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013
M2 - Wed Apr 17, 4:06AM CDT
Research and Markets has announced the addition of the Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013 report to their offering. 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections. Scope - A snapshot of the global therapeutic scenario for Cytomegalovirus (HHV-5) Infections. - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2012
M2 - Tue Feb 26, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pkw3p/severe_acute) has announced the addition of Global Markets Direct's new report "Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2012" to their offering. 'Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection. Scope - A snapshot of the global therapeutic scenario for Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection. - A review of the Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection products under development by compani
Intestinal Cancer - Pipeline Review, H2 2012 Includes a Snapshot of the Global Therapeutic Scenario for Intestinal Cancer
M2 - Thu Jan 17, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/qkchs6/intestinal_cancer) has announced the addition of Global Markets Direct's new report "Intestinal Cancer - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Intestinal Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Intestinal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intestinal Cancer. Intestinal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Normal 0 false false false MicrosoftI
(0)
(0)Accel Entertainment, Inc. (ACEL) Stock Research Links
Scroll down for more posts ▼